Achieve your breakthrough with legal, clinician-prescribed ketamine therapy.

“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy.” — Dr. Stanislav Grof

Mental healthcare is the #1 public health crisis in the developed world, with most people reporting feeling depressed, anxious, stressed, or purposeless despite countless available treatments.

In the scientific and medical communities, psychedelic medicine is increasingly being viewed as the future of behavioral health. Ketamine therapy is growing exponentially, MDMA-assisted therapy is in Phase III clinical trials, and psilocybin-assisted therapy is in Phase II. However, we're still in the first inning and available legal options are limited, expensive, and hard to access

At MindBloom, we're clinicians, technologists, and researchers partnering to increase access to science-backed psychedelic medicine treatments, starting by reducing the cost of ketamine therapy by over 65%.

MindBloom's CEO is a 3x entrepreneur and ketamine patient with both $100M+ in funding and an exit in his prior startups, and our Medical Director is a foremost psychedelic researcher and ketamine therapy provider.

Insider Tip: We're the first VC-backed, direct-to-consumer psychedelic therapy company. Our investors, including Founders Fund, are some of the largest in healthcare technology and psychedelic medicine, having backed Oscar, Hims, ZocDoc, Compass Pathways, and Atai Life Sciences.

No Current Job Openings

Sign Up to see jobs from other companies like Mindbloom.